SAN DIEGO, Nov. 30, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes place virtually Dec. 6-9, 2020. Cidara will highlight analyses from the completed Phase 2 STRIVE trial of rezafungin for treatment of candidemia and/or…

Employee feedback places Cidara among top 20 small companies in the areaSAN DIEGO, Nov. 16, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the fourth consecutive year. Cidara ranked among the top 20 small companies and was the only…

SAN DIEGO, Nov. 11, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCONx Conference. Stifel 2020 Virtual Health Conference Date:Tuesday, November 17, 2020Time:2:00 PM Eastern TimeFormat:Presentation A…

SAN DIEGO, Nov. 05, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities. "We continue to make important progress advancing rezafungin through Phase 3 clinical development. Based on current enrollment trends, we now anticipate top-line data…

Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections Posters presenting new analyses from completed Phase 2 STRIVE trial support the efficacy and pharmacokinetics of once-weekly rezafungin in the treatment of candidemia and invasive candidiasis Oral and poster presentations highlight potential of antiviral conjugates (AVCs) for universal prevention and treatment of influenza SAN DIEGO, Oct. 21, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting…

SAN DIEGO, Oct. 13, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two posters at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting, which takes place virtually from October 19-30, 2020. Data being presented will highlight rezafungin, the Company's novel once-weekly echinocandin currently being evaluated in pivotal…

SAN DIEGO, Sept. 14, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral abstracts and seven posters at IDWeek 2020, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases…

SAN DIEGO, Sept. 02, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in four investor conferences in September: Citi's 15th Annual BioPharma Conference, H.C. Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference, and Maxim Conference: A Too Quiet Pandemic…

SAN DIEGO, Aug. 13, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June 30, 2020, and provided an update on its corporate activities and product pipeline. "We are pleased to have dosed the first patient in our Phase 3 ReSPECT trial, which is evaluating rezafungin for the…

SAN DIEGO, Aug. 04, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020. Presentation Information:Date:Tuesday, August 11, 2020Time:3:30 PM ETWebcast:A live audio webcast and replay of the presentation will be available…